Group 1 - The company announced the completion of a placement agreement on January 20, 2026, successfully placing a total of 2.1 million shares at a price of HKD 92.85 per share to at least six subscribers [1] - The 2.1 million shares represent approximately 0.70% of the existing issued H shares and about 0.53% of the total issued shares of the company, with the post-placement issued H shares increasing to about 0.69% [1] - The total proceeds from the placement amount to approximately HKD 195 million, with a net amount of about HKD 190 million after deducting placement commissions and related costs, resulting in a net issue price of approximately HKD 90.54 per share [1] Group 2 - The company plans to allocate approximately 60% of the net proceeds, or about HKD 114 million, to fund clinical trials for its core product Tinengotinib in the treatment of cholangiocarcinoma (CCA) and other indications [2] - About 30% of the net proceeds, or approximately HKD 57.04 million, will be used for the research and development of other products, including TT-00973, TT-01488, and other molecules [2] - Approximately 10% of the net proceeds, or about HKD 19.01 million, will be allocated for working capital and general corporate purposes [2]
药捷安康-B完成配售合共210万股，净筹约1.9亿港元